Executive compensation, internal targets, valuation gap, gross margin and Q1 earnings preview
HIMS CEO compensation is heavily tied to stock performance, which aligns incentives. Internal targets were nearly achieved despite a high bar. The price pullback deepens the valuation gap versus analyst consensus. Gross margin compression needs monitoring at Q1 earnings.
Executive compensation
- Dudum 2025 total
$22.96 million
- Employee median
$84,402
- Interpretation
Pay is heavily tied to stock price performance, so the CEO's interests are highly aligned with shareholders. This is a positive signal for a founder CEO.
- Ratio
272x
- Shareholder vote
The 11 June AGM will vote on the executive compensation plan.
- Source
DEF 14A proxy filing
- Structure
Base salary is flat on 2024. Most of the pay is stock options, a long-term, non-cash incentive.
Gross margin signal
- Condition
Acceptable if subscriber growth makes up for it
- Trend
Compression of about 500bps over recent quarters, noted in multiple analyses
- Watch
Q1 earnings on 11 May are the key focus. The compression is the unavoidable cost of moving from a compounded to a branded drug distribution model.
Internal targets
- Adjusted EBITDA target achievement
98%
- Disclosure
Disclosed for the first time
- Interpretation
Management sets challenging targets, not ones that are easy to beat, and nearly fully achieved them.
- Revenue target achievement
94%
Price action
- Analyst consensus target
about $32.53
- Change
-5.30%
- 29 Apr close
$26.43
- Most bearish
Morgan Stanley, $21
- Most bullish
JPMorgan, $35 (Overweight)
- 25 Apr peak
$31
- Pullback drivers
The overhang from the Amazon One Medical narrative, plus risk-off sentiment ahead of earnings.
- Pullback from peak
-14.7%
- Upside from current price
about 23%
Q1 earnings preview
- Date
11 May 2026 (after market close)
- Days to earnings
11
- EPS estimate
$0.06 (YoY -70%)
- Key items to watch
- Subscriber growth
- Gross margin trajectory
- Progress in the transition to branded drugs
- Outlook for the peptide business
- Revenue estimate
$621 million (YoY +6%)
Sources (1)
- DEF 14A proxy filing, analyst consensus data, market data for 29 Apr 2026
A brief is a lead for our research, not a verified conclusion or advice.